Genome-wide miRNA screen identifies novel regulators of LDLR activity. (a) Schematic workflow of the primary screen and the bioinformatic analysis. 1,719 miRNA mimics arrayed in five plates were screened in triplicate (5 plates × 3). (b) Linear regression analysis of DiI-LDL mean average intensity (MAI) for plate sets 1 and 2 (top), plate sets 2 and 3 (middle) and plate sets 1 and 3 (bottom). The goodness-of-fit (r 2 ) and regression line (indicative of overall reproducibility of the screen) are indicated in red on each graph. critical component of the cholesterol regulatory circuitry, e.g., miR-33 cooperates with its host SREBF genes in a negative feedback loop to regulate intracellular lipid levels, whereas the SREBP2-induced cluster of miR-96, miR-182 and miR-183 controls cholesterol homeostasis by affecting nuclear SREBP accumulation [16] [17] [18] . A number of miRNAs that control lipid metabolism in vivo have also been identified (such as miR-122, miR-30c, miR-33a, miR-33b, miR-144 and miR-223). In particular, studies of miR-33, miR-144 and miR-223 demonstrate the crucial role of miRNAs in regulating cellular cholesterol efflux and HDL biogenesis [19] [20] [21] [22] [23] [24] . miR-122, whose expression is highly restricted to the liver, has been linked to the regulation of cholesterol and fatty acid synthesis through loss-of-function experiments in both mice and nonhuman primates [25] [26] [27] , and miR-30c regulates lipoprotein assembly by targeting the microsomal triglyceride transfer protein (MTP), a protein that is crucial for the assembly of apolipoprotein B (APOB)-containing lipoproteins 28 . Although these studies highlight the therapeutic potential of manipulating miRNAs to control HDL-C levels, cholesterol biosynthesis and very-low-density lipoprotein (VLDL) secretion, the effects of miRNAs on LDLR activity, and thus on LDL-C, remain poorly understood.
RESULTS

Primary miRNA screen design and optimization
To systematically identify miRNAs that regulate LDLR activity, we developed a high-throughput microscope-based screening assay to monitor the effect of miRNA overexpression on 3,3′-dioctadecylindocarbocyanine-LDL (DiI-LDL) uptake in human hepatic (Huh7) cells (Fig. 1a) . To avoid the confounding effects of the lipoproteins in the media, we initially characterized the specific uptake of DiI-LDL in Huh7 cells incubated in 10% lipoprotein-deficient serum (LPDS). After treatment of the cells with increasing concentrations of DiI-LDL for 8 h, we measured cell-associated DiI fluorescence by flow cytometry. DiI-LDL uptake kinetics were saturable and showed complete saturation at approximately 20-40 µg/ml DiI-LDL-C ( Supplementary  Fig. 1a,b ), in accordance with the well-known kinetic properties of the LDLR 29, 30 . Similar results were observed when we cultured cells in 384-well plates and measured fluorescence intensity using automated fluorescence microscopy ( Supplementary Fig. 1c ). As expected, LDL uptake was specific, as DiI-LDL accumulation was reduced when cells were incubated in the presence of a 30-fold excess of unlabeled LDL (Supplementary Fig. 1d ). We further analyzed whether our system was suitable for functional genomic studies by assessing LDLR gene inactivation by RNA interference (RNAi). Notably, treatment of Huh7 cells with an siRNA directed against LDLR (siLDLR) substantially reduced LDLR expression at the protein level ( Supplementary  Fig. 1e ) and diminished DiI-LDL uptake ( Supplementary Fig. 1f,g ). The Z′-factor (which is a measure of statistical effect size in highthroughput screenings) was > 0.5 ( Supplementary Fig. 1f ), indicative of a robust screen 31 .
Identification of miRNAs that regulate LDLR activity
For the genome-wide miRNA screen, Huh7 cells were transfected in triplicate with a library of 1,719 distinct miRNA mimics and incubated with 30 µg/ml DiI-LDL-C. After 8 h of incubation, the cells were washed, fixed and stained with Hoechst dye (Fig. 1a) . In addition to the internal controls that were included with each screening replicate (see Online Methods), previously validated siRNAs against LDLR and a nonsilencing control siRNA were used as positive and negative controls, respectively ( Supplementary Fig. 1f,g ). The mean average intensity of DiI-LDL uptake was determined on an individual-cell basis using automated high-content image analysis software. To standardize measurements from different plates, the phenotypic effects of each miRNA that increased or decreased average DiI intensity were converted to robust z-scores on the basis of the median average intensity of each array plate 32 . Notably, comparisons of plate replicates and internal plate controls indicated high reproducibility of the screen (Fig. 1b,c) . Upon normalization, robust z-scores for each individual miRNA were ranked and compared to their respective plate replicates (Supplementary Table 1 ). Whereas the screen identified miRNAs that increased or decreased LDL uptake, we chose to focus on miRNAs whose overexpression decreased receptor activity, as pharmacological inhibitors of this miRNA subset represent potential therapeutic agents to lower LDL-C levels.
To narrow down candidates, we designed a multistep system in which miRNAs were subjected to four screening passes before being chosen for further validation (Fig. 1a) . In the first pass, a miRNA was considered to be a putative regulator of LDLR activity if it reduced DiI-LDL fluorescence (robust z-score ≤ −1.5) in at least two of the replicate screening plates (Fig. 1d) . Although this criterion is less stringent than most cut-offs for high-throughput screenings 32 , this pass was designed to yield a substantially higher hit rate (159 miRNAs, ~9.2% of miRNAs screened) to allow for subsequent screening passes (Supplementary Table 1) .
To minimize the risk of identifying false positives, the ensuing screening passes required the candidate miRNAs to be highly expressed in human and/or mouse liver, to be active in the liver (i.e., increased miRNA expression is associated with reduced target gene expression) and to be modulated by dietary lipids (Fig. 1a) . Of the 159 miRNAs identified from the initial pass, five miRNAs (miR-140, miR-128, miR-148a, miR-148b and miR-193b; ~0.29% of miRNAs screened) met these cut-offs, with miR-148a emerging as a strong positive hit-showing medium-to-high expression in human and mouse hepatic tissues [33] [34] [35] , high liver activity 36 and differential expression in the livers of mice fed a high-fat diet (HFD) 35 (Supplementary Table 2 ). Of note, it has recently been shown that single-nucleotide polymorphisms (SNPs) in the promoter region of MIR148A are associated with altered LDL-C and triglyceride levels in humans [37] [38] [39] , suggesting a possible physiological role for this miRNA in regulating lipid metabolism and highlighting this miRNA for further study.
miR-148a expression is regulated by hepatic lipid content MIR148A is encoded within an intergenic region of human chromosome 7 and is highly conserved among vertebrate species (Supplementary Fig. 2a ). In agreement with previous reports 35 , Mir148a was highly expressed in mouse liver (Supplementary Fig. 2b ) and was upregulated in the livers of HFD-fed mice ( Supplementary  Fig. 2c) . Additionally, we found that the expression of Mir148a was substantially increased in the livers of HFD-fed rhesus monkeys (Supplementary Fig. 2d ). In accordance with this result, and consistent with previous observations 40 , the mature form of Mir148a was also markedly upregulated in the livers of leptin-deficient genetically obese (ob/ob) mice (Supplementary Fig. 2e) .
To gain insight into the functional role of miR-148a in cholesterol homeostasis, we analyzed its potential targets using a rigorous bioinformatic algorithm 41 . Predicted targets identified by three targetprediction websites (TargetScan, miRWalk and miRanda) [42] [43] [44] were assigned to functional annotation clusters using the public gene ontology database DAVID 45 . As shown in Supplementary Table 3 , miR-148a target genes were enriched (E ≥ 1.0) within 78 clusters and several annotation networks. This functional cluster analysis was combined with data on known and predicted associations between individual miR-148a target genes that are enriched in lipid metabolism using the STRING v9 (ref. 46 ) and PANTHER databases 47 . From this bioinformatic analysis (Supplementary Fig. 3a) , miR-148a Fig. 3b) . To assess the effect of miR-148a on LDLR expression, we first performed ribonucleoprotein immunoprecipitation (RNP-IP) using an antibody specific to argonaute-2 (AGO2), a component of the RNA-induced silencing complex (RISC) that mediates miRNA-directed gene silencing. Overexpression of miR-148a significantly enriched the association of LDLR mRNA with the AGO2-containing complex (Fig. 2a) , suggesting that LDLR expression is directly regulated by miR-148a. Additionally, overexpression of miR-148a markedly reduced LDLR 3′ UTR activity as compared to that in control-transfected cells (Fig. 2b) . Notably, combined mutation of the two miR-148a target sites relieved miR-148a-mediated repression of LDLR 3′ UTR activity (Fig. 2b) .
We then determined the effect of miR-148a on LDLR mRNA and protein expression. Transfection of Huh7 cells with miR-148a, but not with a control mimic (CM), significantly decreased LDLR mRNA and protein levels ( Fig. 2c,d) , and the effects of miR-148a were seen at concentrations as low as 10 nM (Fig. 2c,d) . A miR-148a mimic that is mutated in the seed sequence (CM*) was used as a negative control (Supplementary Fig. 4a ). The inhibition of LDLR expression by miR-148a was highly specific because the expression of other cholesterol-related genes, such as SREBF2 and LDLR adapter protein 1 (LDLRAP1), was not influenced by miR-148a overexpression (Fig. 2c) . Notably, inhibition of endogenous miR-148a in Huh7 cells significantly increased the expression of LDLR as compared to that in cells transfected with a control inhibitor (CI) (Fig. 2e,f) . We observed similar results in another human hepatic cell line, HepG2, as well as in mouse hepatic (Hepa) cells ( Supplementary  Fig. 4b-e) . Finally, we found that miR-148a overexpression did not cause a further decrease in LDLR levels in Huh7 cells transfected with siLDLR (Fig. 2g) .
Defective hepatic LDLR activity results in elevated levels of LDL-C in the blood and is associated with an increased risk of coronary artery disease 1, 2 . To assess the role of miR-148a in regulating LDL-C uptake in human and mouse hepatic cells, we overexpressed or inhibited miR-148a and assessed DiI-LDL binding and uptake by flow cytometry. Transfection of Huh7, HepG2 and Hepa cells with miR-148a attenuated DiI-LDL-specific binding ( Fig. 2h and Supplementary Fig. 4f ) and uptake ( Fig. 2h and Supplementary  Fig. 4g ), whereas transfection with an miR-148a antagonist (Inh148a) increased DiI-LDL-specific binding and uptake ( Fig. 2i and Supplementary Fig. 4h,i) . These effects appear to be mediated by the direct targeting of LDLR expression by miR-148a, because LDLR silencing abrogated the effect of miR-148a overexpression on DiI-LDL binding and uptake (Fig. 2h) . Additionally, when we analyzed internalization of an antibody specific to LDLR and DiI-LDL uptake by immunofluorescence, we observed reduced LDLR internalization and a concomitant decrease in DiI-LDL uptake in Huh7 cells overexpressing miR-148a as compared to cells transfected with a negative control mimic (Fig. 3a,b) . Consistent with these results, transfection of Huh7 cells with miR-148a significantly reduced the intracellular cholesterol concentration after incubation with unlabeled native LDL (nLDL) as compared to that in CM-treated cells (Fig. 3c) . Notably, the intracellular cholesterol concentration was increased in Huh7 cells overexpressing an inhibitor of miR-148a (Fig. 3d) , confirming the endogenous role of miR-148a in modulating cholesterol uptake.
We next determined whether the effect of miR-148a in regulating LDL binding and uptake could be rescued by overexpressing an LDLR-GFP cDNA construct lacking the 3′ UTR, which is thereby resistant to the inhibitory action of miR-148a. The significant reduction in DiI-LDL binding and uptake induced by miR-148 in Huh7 cells, as analyzed by immunofluorescence, was abrogated in cells that expressed the LDLR-GFP construct (Fig. 3e,f) . In these experiments, transfection of the LDLR-GFP construct led to massively increased DiI-LDL binding and uptake. However, these results, together with our previous observation that miR-148a overexpression does not influence DiI-LDL uptake in cells transfected with siLDLR ( Fig. 2h) , suggest that miR-148a regulates DiI-LDL binding and uptake by direct downregulation of LDLR expression. Alternatively, miR-148a could be acting upstream or downstream of LDLR. Taken together, these results demonstrate that manipulation of cellular levels of miR-148a alters LDLR activity.
Transcriptional regulation of miR-148a by SREBP1c
Given that miR-148a levels are regulated by dietary lipids 35 , we next sought to determine how this miRNA is transcriptionally regulated. Previous computational methods have identified several transcriptional start sites (TSSs) located ~1.1 to ~1.6 kb upstream of the MIR148A sequence 48, 49 . Notably, these TSSs correlate with epigenetic signatures and adjacent active promoter and enhancer regions that are involved in the regulation of MIR148A expression 50, 51 ( Supplementary Fig. 5a ). Intriguingly, using chromatin immunoprecipitation combined with massively parallel sequencing (ChIP-seq), an SREBP1-binding site as well as binding sites for generic transcription factors involved in SREBP1 activation (Sp1 and Nfy) were previously identified in the adjacent active promoter region of miR-148a (ref. 52 ). Additionally, we identified several other conserved SREBP1-binding sites (E-box elements, 5′-CANNTG-3′) using target-prediction algorithms (Supplementary Fig. 5b ). As it has been reported that SREBP1c is increased in the livers of ob/ob mice and under HFD-fed conditions 53 , we reasoned that SREBP1c, the predominant isoform of SREBP1 in the liver 54 , probably acts as a transcriptional regulator of miR-148a expression. To test whether SREBP1c modulates miR-148a expression, we transfected Huh7 cells with a vector expressing FLAG-tagged nuclear SREBP1c (nSREBP1c) and measured miR-148a expression. Overexpression of nSREBP1c significantly increased the expression of MIR148A (both the precursor and mature forms) as well as that of the SREBP1c target gene FASN (Fig. 4a) . To further explore the in vivo relevance of SREBP1c-dependent regulation of miR-148a, we measured levels of the mature form of miR-148a in the livers of mice that had been fasted for 24 h and subsequently re-fed a high-carbohydrate, low-fat diet for 12 h, a dietary condition that increases endogenous SREBP1c expression 55 . As expected, levels of both the precursor and the mature Mir148a paralleled the re-feeding-induced increase in mRNA levels of Fasn and the SREBP1c-encoding isoform of Srebf1, as assessed by qRT-PCR (Fig. 4b) . We observed similar results for hepatic pre-Mir148a and Mir148a expression in fasted and re-fed mice by northern blotting (Fig. 4c) .
LXR activates SREBP1c expression 56, 57 . To ascertain whether miR-148a expression is regulated by LXR, we treated primary mouse hepatocytes and Huh7 cells with the synthetic LXR ligand T0901317 (T090) and measured miR-148a expression. LXR activation led to a significant upregulation of the expression of the mature SREBP1 protein as well as an increase in the mRNA levels of Fasn, the SREBP1c-encoding isoform of Srebf1 (Fig. 4d and Supplementary  Fig. 6a ) and the precursor and mature forms of Mir148a (Fig. 4e  and Supplementary Fig. 6b ). To determine whether the induction of miR-148a expression by LXR is dependent on SREBP1c, we silenced SREBF1 using RNA interference. The efficiency of siRNA knockdown was confirmed by qRT-PCR and western blotting ( Supplementary  Fig. 6c ). After treatment with T090, MIR148A levels were markedly increased in cells that were treated with a control siRNA but not in those that were treated with a siRNA to SREBF1 ( Supplementary  Fig. 6d,e) , suggesting that SREBP1c is responsible for the induction of miR-148a expression by LXR.
We further investigated the role of SREBP1c in regulating miR-148a expression by generating luciferase reporter constructs containing 
Overexpression of nSREBP1c increased MIR148A promoter activity as compared to that observed in cells transfected with an empty vector (Fig. 4f) . In agreement with this result, LXR-mediated induction of endogenous SREBP1c by T090 also significantly increased MIR148A promoter activity (Fig. 4g) , confirming that SREBP1c regulates MIR148A at the transcriptional level.
The promoter region of human MIR148A contains four E-box elements, three of which are conserved in mice ( Supplementary  Fig. 5b) . To test which E-box elements are responsible for the SREBP1c-mediated induction of MIR148A transcription, we designed miR-148a promoter constructs with deletions of each of the three conserved E-box motifs (herein named E-box2, E-box3 and E-box4, respectively). Deletion of each of these E-boxes significantly attenuated SREBP1c-dependent promoter activity (Fig. 4h) . Moreover, when all three conserved E-box elements were simultaneously deleted, miR148a reporter activity was further diminished upon nSREBP1c overexpression, suggesting that SREBP1c acts through E-box2, E-box3 and E-box4 to fully induce MIR148A transcription. Indeed, when we transfected cells with a shortened promoter construct (p148a-lucT) lacking the nonconserved E-box1 motif, MIR148A promoter activity was unaffected (Supplementary Fig. 6f) .
Finally, to assess whether Srebp1 binds directly to the Mir148a promoter, we performed ChIP assays from the livers of mice that were fasted for 24 h or that had been fasted for 24 h and subsequently re-fed a high-carbohydrate, low-fat diet for 12 h (Fig. 4i) . We found that Srebp1 was significantly enriched in the promoters of Srebf1, Fasn and Mir148a upon re-feeding. Notably, no Srebp1 enrichment was observed in an upstream region of the Mir148a promoter that lacks Srebp1-binding sites (uNeg). Moreover, we found an enrichment of Mir148a and Ldlr mRNAs in RISC complexes from the livers of mice that had been fasted and subsequently re-fed (Fig. 4j) . Altogether, these results provide compelling evidence that Srebp1c directly regulates the transcriptional expression of the Mir148a gene by binding to the E-box2, E-box3 and E-box4 elements and that Srebp1c controls miR-148a expression in vivo.
Modulation of miR-148a expression alters plasma lipids in vivo
In light of the role of miR-148a in negatively regulating LDLR expression and activity in vitro, we next assessed the functional effects of inhibiting miR-148a in vivo. Because the rate of hepatic LDL clearance is 40-fold greater in wild-type C57BL/6 mice than in humans 58 , we used for our studies mice that express a human apolipoprotein B (APOB) transgene (which encodes the APOB100 isoform) in an Ldlr heterozygote background (APOBTg;Ldlr −/+ ) and thus display an LDL-and HDL-dominant lipoprotein profile (Supplementary Fig. 7) . To inhibit miR-148a expression, male APOBTg;Ldlr −/+ mice were injected every 3 d for a period of 2 weeks with 5 mg per kg of body weight (mg/kg) of locked nucleic acid (LNA) antisense oligonucleotides targeting miR-148a (LNA 148a) (Fig. 5a) . A scrambled LNA oligonucleotide was used as a control (LNA control). Twenty-four hours after the last injection, the mice were killed and the sera and livers were collected for plasma cholesterol and gene expression analysis, respectively. Treatment with LNA 148a markedly decreased the levels of hepatic Mir148a (Fig. 5b) and significantly increased hepatic LDLR expression (Fig. 5c ) as compared to that in controls. Consistent with these results, fractionation of plasma lipoproteins revealed a marked decrease in LDL-C levels in APOBTg;Ldlr −/+ mice treated with LNA 148a (Fig. 5d-f) . Notably, inhibition of miR-148a also significantly increased HDL-C levels (Fig. 5d,f) . As expected by the significant npg decrease in the LDL-C and increase in the HDL-C fractions, the expression of APOB100 and APOA1 was diminished and enhanced, respectively, in pooled plasma samples isolated from mice treated with LNA 148a as compared to those in the controls (Fig. 5e) . Similar effects on plasma lipoprotein distribution and apolipoprotein expression were observed in a separate cohort of mice ( Supplementary  Fig. 8a-c) . Total plasma cholesterol levels were slightly, but not significantly, decreased in mice treated with LNA anti-miR-148a (Fig. 5f) , consistent with the finding that miR-148a antagonism has opposing effects on LDL-C and HDL-C. LDL-C levels in Ldlr −/− mice were unaffected by LNA 148a treatment (Supplementary Fig. 9) , indicating that the effect of miR-148a on LDL-C levels is mediated by the LDLR. The effects of LNA 148a on lipoprotein metabolism were not influenced by liver toxicity, as indicated by similar blood levels of alanine transaminase (ALT), asparagine transaminase (AST), albumin and total bilirubin in LNA 148a-and LNA control-treated mice (Fig. 5g) . Moreover, Mir148a silencing did not affect body weight (Fig. 5h) or hepatic lipid accumulation (Fig. 5i,j) .
The impact of anti-miR-148a treatment on lipoprotein metabolism was confirmed in APOBTg;Ldlr −/+ mice fed an HFD for 1 month (Supplementary Fig. 10a-c) . Similarly to the results in chow diet-fed mice (Fig. 5c) , HFD-fed mice treated with LNA 148a had increased levels of hepatic LDLR (Supplementary Fig. 10d ), a marked decrease in LDL-C and a marked increase in HDL-C levels ( Supplementary  Fig. 10f,g ). LNA 148a treatment did not affect body weight or hepatic lipids ( Supplementary Fig. 10h-j) .
To gain a better understanding of how miR-148a might regulate HDL-C levels in vivo, we analyzed additional predicted miR-148a target genes. Of note, we found a conserved predicted miR-148a-binding site within the 3′ UTR of ABCA1 (Supplementary Fig. 3a,c) . Given that ABCA1 has a major role in regulating HDL biogenesis in the liver 59 , we hypothesized that the increased HDL-C levels observed in LNA 148a-treated mice is due to miR-148a-mediated regulation of ABCA1. Indeed, we found a substantial increase in hepatic ABCA1 protein levels in LNA 148a-treated mice as compared to that in controls ( Fig. 6a; Supplementary Fig. 10e ).
miR-148a directly targets the 3′ UTR of ABCA1
To assess whether miR-148a targets Abca1, we first performed ribonucleoprotein immunoprecipitation (RNP-IP) using an Ago2-specific antibody from the livers of mice that were fasted or that had been fasted and then re-fed a high-carbohydrate diet, a condition that enriches miR-148a in the RISC complex (Fig. 4j) . Re-feeding significantly enriched the association of Abca1 mRNA in Ago2-containing complexes (Fig. 6b) , suggesting that miR-148a regulates ABCA1 under physiological conditions. Luciferase reporter assays revealed a significant downregulation of human ABCA1 3′ UTR activity in cells transfected with a miR-148a mimic, as compared to control cells (Fig. 6c) . Of note, specific point mutations in the predicted miR148a-binding site (PM1) abolished the inhibitory effect of miR-148a on ABCA1 3′ UTR activity (Fig. 6c) . To determine whether miR-148a regulates ABCA1 expression and cholesterol efflux in human hepatic cells, we transfected Huh7 cells with a miR-148a mimic or inhibitor. miR-148a overexpression strongly reduced ABCA1 mRNA and protein levels under both basal conditions (vehicle) and after treatment with T090 to directly stimulate LXR-dependent ABCA1 expression (Fig. 6d,e) , and it also significantly attenuated cholesterol efflux to APOA1 (Fig. 6f) . Inhibition of endogenous miR-148a in Huh7 cells increased ABCA1 mRNA and protein levels and resulted in elevated cholesterol efflux to APOA1 (Fig. 6g-i) . Taken together, these experiments identify ABCA1 as a direct target of miR-148a.
DISCUSSION
Our data support the importance of miRNAs in contributing to the regulatory circuitry of cholesterol metabolism, particularly with respect to the SREBPs. Notably, the role of miR-33a and miR-33b (miR-33a/b) in controlling lipid homeostasis has been extensively studied. miR-33a and miR-33b are located within the introns of the SREBF2 and SREBF1 genes, respectively. Both miR-33a and miR-33b are cotranscribed with their host genes under conditions that increase SREBP activation and act to control cholesterol and fatty acid homeostasis by targeting genes involved in cellular cholesterol efflux and fatty acid oxidation. Moreover, miR-185 was recently shown to regulate cholesterol homeostasis in concert with the genes encoding the SREBPs. In particular, miR-185 is transcriptionally activated by SREBP1c and negatively regulates SREBP2 expression, thereby inhibiting de novo cholesterol biosynthesis and LDL uptake 60 . Here we show that miR-148a directly controls LDLR activity and is transcriptionally activated by SREBP1c in vitro and in vivo. Similarly to miR-185, LXR-mediated induction of SREBP1c results in increased expression of miR-148a. These results suggest that LDLR expression is regulated by the SREBP1c-dependent induction of miR-148a; however, we cannot rule out the possibility that the LXR-mediated decrease in LDLR expression could also be due to an increase in miR-185 or IDOL expression. Given that IDOL is not highly expressed in mouse liver, further studies in nonhuman primates are needed to assess the physiologic contribution of each pathway to the post-transcriptional regulation of hepatic LDLR expression in humans.
In addition to miR-33 and miR-185, the locus comprising miR-96, miR-182 and miR-183 (miR-96/182/183) also acts in a feedback loop to regulate cholesterol metabolism. This locus is directly regulated by SREBP2 and regulates activation of SREBP2 by controlling its processing (via targeting of insulin-induced gene 2 (INSIG2)) and stability (via targeting of F-box and WD repeat domain containing 7 (FBXW7)) in cultured cells 18 . Of note, antagonism of miR-182 in mice had no significant effect on circulating cholesterol and triglyceride levels. Because these studies were conducted in wild-type mice, which have an HDL-dominant lipoprotein profile, future studies using 'humanized' mouse models may yield alternative results.
For our in vivo analysis, we employed the APOBTg;Ldlr −/+ mouse model, which displays an LDL-dominant lipoprotein profile, and found a significant decrease in LDL-C when hepatic miR-148a levels were antagonized. As a major route for the clearance of APOE-and APOB-containing lipoproteins is LDLR-mediated endocytosis in the liver 58 , the reduction in LDL-C by miR-148a antagonism is likely to be due mainly to miR-148a-mediated repression of hepatic LDLR expression. Although the possibility exists that miR-148a affects other pathways that control lipid metabolism, our data unequivocally establish a key role for miR-148a in regulating LDLR activity in vivo. We also provide evidence that miR-148a post-transcriptionally controls hepatic ABCA1 expression and cellular cholesterol efflux to APOA1, such that antagonism of miR-148a significantly increases circulating HDL-C levels in vivo.
Human genetic data suggests that miR-148a has a role predominantly in governing LDL-C metabolism, as a SNP (rs4722551) in the MIR148A promoter region is strongly associated with altered LDL-C levels in humans [37] [38] [39] . Here we provide insight into the mechanism by which this variant might alter plasma LDL-C levels: by affecting npg transcriptional activation of MIR148A and, consequently, LDLR expression. Future experiments are warranted to dissect the contribution of this variant to altered lipid levels and cardiovascular disease risk.
In conclusion, our results underscore the importance of miRNAs in the post-transcriptional regulation of LDLR activity. Specifically, because suppression of miR-148a activity simultaneously reduces LDL-C and increases HDL-C concentrations, our data highlight the therapeutic potential of this approach for the treatment of atherosclerosis and related dyslipidemias.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Materials.
For the LDLR-GFP plasmid, human LDLR cDNA was cloned into the pEGFP-N3 vector (Clontech). The pcDNA3.1-2×FLAG-SREBP1c vector (#26802) and empty control vector were from Addgene. Chemicals were obtained from Sigma-Aldrich unless otherwise noted. The synthetic LXR ligand T0901317 (T090) was purchased from Cayman Chemical. Human APOA1 was obtained from Meridian Life Sciences. Lipoprotein-deficient serum (LPDS) was prepared from FBS delipidated with 4% fumed silica. 1,1′-dioctadecyl-3,3,3,3′-tetramethylindocarbocyanineperclorate (DiI) was purchased from Molecular Probes (Invitrogen). Mouse monoclonal antibodies against ABCA1 (#ab18180) and APOA1 (#ab20453) were purchased from Abcam. Rabbit polyclonal antibodies against LDLR (#1007665) and SREBP1 (clone C-20, #sc-366) were from Cayman Chemical and Santa Cruz, respectively. Mouse monoclonal antibodies against HSP90 (#610418) and p84 (clone 5E10, #GTX70220) were purchased from BD Bioscience and GeneTex. Mouse monoclonal antibodies against LDLR (clone C7, #sc-18823) and SREBP1 (clone 2A4, #NB600-582) were obtained from Santa Cruz and Novus, respectively. Normal IgG (#2729) and ChIP-grade rabbit polyclonal antibodies against SREBP1 (clone H-160, #sc-8984X) were purchased from Cell Signaling and Santa Cruz, respectively. A mouse monoclonal antibody against APOB (#K23300R) was purchased from Meridian Life Sciences. A mouse monoclonal antibody against AGO2 (clone 2D4, #014-22023) was purchased from Wako Chemicals. Secondary fluorescently labeled antibodies were from Molecular Probes (Invitrogen). miRNA mimics and inhibitors were obtained from Dharamcon. A scrambled miR-148a mimic (CM*) was designed and purchased from Dharmacon. siRNAs were purchased from Dharmacon and locked nucleic acid (LNA) miRNA detection probes were purchased from Exiqon (Woburn, MA). For in vivo experiments, miRCURY locked nucleic acid (LNA) miRNA inhibitors targeting mature Mir148a or a scrambled control was purchased from Exiqon. Image acquisition and analysis. Automated high-content and high-throughput images were acquired using an Arrayscan VTI HCS Reader (Thermo Scientific) with a Zeiss 10× objective. 384-well plates were loaded onto the microscope using a Catalyst Express robotic arm and imaged overnight. In each well, cell nuclei and DiI-LDL intensities were imaged in five predefined fields. Image data was analyzed using BioApplication's Target Activation V3 image analysis software (Thermo Scientific). Briefly, nuclei were first identified on the Hoechst stain (channel 1). Following this, cell boundaries were estimated using the geometric segmentation method and used to calculate DiI intensity (channel 2) within each cell. Valid object count, mean average intensity and total average intensity of DiI were recorded for each field. For the primary screen, 57,600 images, consisting of an average of 533,528 objects/plate, were analyzed.
Hit classification. miRNAs were scored on their ability to significantly increase or decrease DiI intensity as compared to that of negative controls. Cytotoxic miRNA overexpression phenotypes were filtered for hit classification by excluding wells in which fewer than 500 cells were identified as valid objects. In addition, 32 validated internal controls, including nonsilencing (NS) siRNAs and siRNAs against LDLR (Fig. 1) , as well as nontargeting negative-control miRNAs (control mimics) and siRNAs targeting KIF11 (Life Technologies), were used on each plate to monitor transfection efficiency. After confirming efficient transfection efficiency, mean average intensities of each well were normalized to plate medians and converted to robust z-scores using Matlab, as previously described 32 . Robust z-scores were compared between each plate replicate and the mean of each score was calculated and used to rank potential candidates. Those miRNAs that had a robust z-score of ≤ −1.5 (159 miRNAs, 9.2% of miRNAs screened) were chosen for further characterization. To narrow down candidate miRNA genes, hits were subjected to several screening passes (Fig. 1a,  bottom) . Briefly, candidates were filtered on the basis of whether they were highly expressed in mouse or human liver (nine miRNAs, 0.52% of miRNAs screened), were active in the liver (eight miRNAs, 0.46% of miRNAs screened) and were previously shown to respond to dietary lipids (five miRNAs, 0.29% of miRNAs screened).
Bioinformatic analysis of miRNA target genes.
Target genes for miR-148a were identified and compared using the online target prediction algorithm, miRWalk (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/), which provides target interaction information from eight different prediction algorithms. Specifically, the programs miRanda, miRWalk and TargetScan 6.2 were used. Putative targets for miR-148a that were identified by all three of these algorithms (2,217 targets) were uploaded into DAVID v6.7 for functional annotation clustering (http://david.abcc.ncifcrf.gov). 'High' classification stringency settings yielded 398 functional annotation clusters for miR-148a (Supplementary Table 3) , of which 78 clusters (miR-148a) were highly enriched (E ≥ 1.0). In another set of analyses, we took the putative targets for miR-148a that were identified above and uploaded them into the gene classification system PANTHER v8.0 (http:// www.pantherdb.org) to identify gene targets that mapped to the lipid metabolic process (GO:0006629). The functional interactions of these predicted targets (110 targets for miR-148a) as described in STRING v9.05 (http://string-db.org) were then combined with the functional annotation groups described in DAVID. Matlab and Cytoscape v2.8.3 were used to create the visualization networks, as previously described 41 . STRING interactions with a confidence score of 0.4 or higher were added and are highlighted in gray. Smaller annotation clusters and unconnected genes were left out of the visualization due to space constraints. siRNA, miRNA mimic and miRNA inhibitor transfections. For siRNA transfections, Huh7 cells were transfected with 20 nM of SMARTpool ONTARGETplus LDLR siRNA or 20 nM of ON-TARGETplus nontargeting pool for 48 h in LPDS medium or 60 nM of SMARTpool ON-TARGETplus SREBP1 siRNA or 60 nM of ON-TARGETplus nontargeting pool for 60 h as previously described 61 . Verification of LDLR and SREBP1 knockdown was assessed by western blotting and qRT-PCR analysis, as described below. For mimic and inhibitor transfections, Huh7, HepG2 and Hepa cells were transfected with 40 nM miRNA mimic (miR-148a, 5′-UCAGUGCACUACAGAACUUUGU-3′) (Dharmacon #C-300540-05-0005) or with 60 nM miRNA inhibitor (Inh-148a) (Dharmacon #IH-300540-07-0005) using RNAimax (Invitrogen) or Lipofectamine 2000 (Invitrogen) according to previously established protocols 16 . All experimental control samples were treated with an equal concentration of a nontargeting control mimic sequence (CM, 5′-UCACAACCUCCUAGAAAGAGUAGA-3′) (Dharmacon CN-001000-01-20) or inhibitor negative-control sequence (CI, Dharmacon #IN-001005-01-20) for use as controls for non-sequence-specific npg effects in miRNA mimic or inhibitor experiments. Verification of miR-148a overexpression and inhibition was determined using qRT-PCR, as described below. For dose response experiments, Huh7 cells were transfected with 20 nM of CM or 10, 20, 40 and 60 nM of a miR-148a mimic for 48 h as previously described 16 . In another set of experiments, Huh7 cells were transfected with 40 nM of a miR-148a mimic or 40 nM of a scrambled miR-148a mimic (CM*, 5′-UCUGAGCUCUACAGAACUUUGU-3′). To assess the combined effect of miR-148a overexpression and knockdown of LDLR, Huh7 cells were transfected with 60 nM of a nonsilencing siRNA, with 40 nM of a miR-148a mimic or with both for 48 h in LPDS. Cells were transfected with an equal amount of CM to compensate for total DNA content as previously described 23 RNA isolation and quantitative real-time PCR. Total RNA was isolated using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. For mRNA quantification, cDNA was synthesized using iScript RT Supermix (Bio-Rad), following the manufacturer's protocol. Quantitative real-time PCR (qRT-PCR) analysis was performed in triplicate using iQ SYBR green Supermix (Bio-Rad) on an iCycler Real-Time Detection System (Bio-Rad). The mRNA level was normalized to GAPDH or 18S rRNA as housekeeping genes. For miRNA quantification, total RNA was reverse-transcribed using the miScript II RT Kit (Qiagen). Primers specific for human and mouse pre-Mir148a and Mir148a (Qiagen) were used, and values were normalized to SNORD68 (Qiagen) or 18S rRNA as housekeeping genes. For mouse tissues, total liver RNA from wild-type mice fed a high-fat diet (HFD) was isolated using the Bullet Blender Homogenizer (Next Advance) in TRIzol. One microgram of total RNA was reverse-transcribed and gene or miRNA expression was assessed as above. Primer sequences are available upon request.
Western blot analysis. Cells were lysed in ice-cold buffer containing 50 mM Tris-HCl pH 7.5, 125 mM NaCl, 1% NP-40, 5.3 mM NaF, 1.5 mM NaP, 1 mM orthovanadate, 1 mg/ml of protease inhibitor cocktail (Roche) and 0.25 mg/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF; Roche). Cell lysates were rotated at 4 °C for 1 h before insoluble material was removed by centrifugation at 12,000g for 10 min. Nuclear extracts were prepared using the NE-PER Nuclear Protein Extraction Kit (Thermo Scientific) according to the manufacturer's instructions. After normalizing for equal protein concentration, cell lysates were resuspended in SDS sample buffer before separation by SDS-PAGE. After overnight transfer of the proteins onto nitrocellulose membranes, the membranes were blocked with 5% BSA (wt/vol) in wash buffer and probed overnight at 4 °C with antibodies to the following proteins: ABCA1 (1:1,000), LDLR (1:1,000), HSP90 (1:1,000), SREBP1 (1:1,000) and p84 (1:1,000). Blots were then washed and incubated with fluorescently labeled secondary antibodies (Invitrogen). Protein bands were visualized using the Odyssey Infrared Imaging System (LI-COR Biotechnology). Densitometry analysis of the gels was carried out using ImageJ software from the NIH (http://rsbweb.nih.gov/ij/).
For western blot analysis of APOB100 and APOB48 in lipoprotein fractions, an equal volume of three fractions was mixed with reducing SDS sample buffer and separated on a NuPAGE Novex 4-12% Tris-Acetate Mini Gel using 1× NuPAGE Tris-acetate SDS running buffer (Invitrogen). Following overnight transfer of proteins onto nitrocellulose membranes, the membranes were blocked in 5% (wt/vol) nonfat milk dissolved in wash buffer. The membranes were probed with an antibody against APOB (1:2,000) overnight at 4 °C, washed, incubated with fluorescently labeled secondary antibodies and visualized as above. Western blot analysis of APOA1 (1:1,000) in pooled lipoprotein fractions was also carried out in this manner.
Northern blot analysis. miRNA expression was assessed by northern blot analysis as previously described 63 . Briefly, total RNA (5 µg) was separated on a 15% acrylamide Tris-borate-EDTA (TBE) 8 M urea gel and blotted onto a Hybond N+ nylon filter (Amersham Biosciences). DNA oligonucleotides complementary to mature miR-148a-3p (5′-ACAAAGTTCTGTAGTGCACTGA-3′) were endlabeled with [α-32 P] ATP and T4 polynucleotide kinase (New England Biolabs) to generate high-specific-activity probes. Hybridization was carried out according to the ExpressHyb (Clontech) protocol. Following overnight membrane hybridization with specific radiolabeled probes, membranes were washed once for 30 min at 42 °C in 4× SSC and 0.5% SDS and subjected to autoradiography. Blots were reprobed for 5S rRNA (5′-CAGGCCCGACCCTGCTTAGCTTCC GAGAGATCAGACGAGAT-3′) to control for equal loading.
Ribonucleoprotein immunoprecipitation (RNP-IP)
. AGO2 immunoprecipitation (AGO2-IP) experiments after CM or miR-148a transfection were conducted in Huh7 cells as previously described 64 . Briefly, 1 × 10 7 cells were transfected with 20 nM miR-148a or CM using RNAimax for 24 h. After 24 h, cells were collected and subjected to AGO2-IP using the RNA isolation kit for human AGO2 (Wako Chemicals) according to the manufacturer's instructions. The IP pulldown RNA was used to determine the expression levels of MIR148A and LDLR by qRT-PCR, as described above.
In another set of experiments, RISC complexes were immunoprecipitated from the livers of mice that were fasted for 24 h or fasted for 24 h and re-fed a high-carbohydrate-low-fat diet for 12 h using 5 µg of either an antibody against mouse Ago2 (2D4, Wako) or an IgG control antibody (Cell Signaling) as previously described 65 . Ago2-bound RNA was used to determine the expression levels of Mir148a, Abca1 and Ldlr mRNA as described above. Genes not predicted to be targets of miR-148a (Rn18S, Actb and Rplp0) were used as negative controls.
Chromatin immunoprecipitation (ChIP) assays. Equal portions of frozen liver tissue (~100 mg each) from fasted and re-fed mice were pooled (n ≥ 2 mice per group) and crushed into powder in liquid nitrogen. Liver powders were transferred into microcentrifuge tubes and homogenized in cold 1× PBS plus protease inhibitors. Following homogenization, samples were filtered, resuspended in 10 ml 1× PBS containing 1% formaldehyde and rotated on a shaker for 10 min at room temperature (RT). To quench formaldehyde, glycine was added to a final concentration of 0.125 M and samples were rotated for an additional 5 min at RT. Cells were then collected by centrifugation, washed twice in cold 1× PBS plus protease inhibitors and incubated in 2 ml cold ChIP lysis buffer 1 (50 mM HEPES pH 7.6, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100) for 10 min at 4 °C. The samples were then centrifuged at 3000g at 4 °C for 5 min, incubated with 2 ml cold ChIP lysis buffer 2 (10 mM Tris-HCl pH 8, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) for 10 min at 4 °C and centrifuged at 3,000g for 5 min at 4 °C. The supernatant was removed and the pellet of nuclei was resuspended in 270 µl ChIP lysis buffer 3 (10 mM Tris-HCl pH 8, 0.5% sarkosyl, 0.5 mM EGTA, 1 mM EDTA, 100 mM NaCl, 0.1% sodium deoxycholate). Nuclear lysates were sonicated 3 × 5 min (30 s on and 30 s off) on high using a Diagenode Biorupter (Diagenode, cat #: UCD-200 TO). After checking chromatin size by agarose gel electrophoresis, extracts were clarified by centrifugation at maximum speed for 10 min at 4 °C, precleared with 60 µl of Protein G beads (Millipore #16-201) for 1 h at 4 °C and then incubated overnight at 4 °C with 4 µg of anti-SREBP1 or control rabbit IgG. Antibody-bound complexes were then captured by incubation with 60 µl of Protein G beads for 1 h at 4 °C. Beads were washed once with low-salt immune complex wash buffer (0.10% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 mM NaCl), once with high-salt immune complex wash buffer (0.10% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 500 mM NaCl), twice with LiCl immune complex wash buffer (0.25 M LiCl, 1% NP-40, 1% deoxycholic acid, 1 mM EDTA, 10 mM Tris-HCl) and once with TE (10 mM Tris-HCl pH 8, 1 mM EDTA). Antibody-bound complexes were then eluted by incubation with 200 µl of elution buffer (100 mM NaHCO 3 , 1% SDS) for 15 min with gentle rotation followed by a second 15-min elution with 200 µl of elution buffer. To reverse crosslinks, the eluates were combined, treated with 5 M NaCl and incubated overnight at 65 °C. Samples were then incubated with 1 µl RNase A, incubated for 30 min at 37 °C and treated with 4 µl 0.5 M EDTA, 8 µl 1 M Tris-HCl and 1 µl proteinase K for 1 h at 45 °C. DNA was purified using the QIAquick PCR Purification Kit (QIAGEN) according to the manufacturer's instructions and eluted in 50 µl of TE buffer. qPCR was run as described above using primer sets for the following promoters: Fasn (5′-GCGCAGCCCCGACGCTCATT-3′ and 5′-CGGCGCTATTTAAACC GCGG-3′) and Srebf1 (5′-GTAGCCAATGGGTGCAAGG-3′ and 5′-CACGTG ACCAAAACCAGAGT-3′). Two primer sets were used for the Mir148a promoter, npg both of which gave similar results (5′-AATAAGAGCGCAGGTCGTC-3′ and 5′-GCTGAGCTAGGCTTCCAGT-3′; 5′-GGAACCTGCTGACTTGACAC-3′ and 5′-GACGACCTGCGCTCTTATT-3′). A primer set amplifying a region upstream of the predicted SREBP1-binding sites in the Mir148a promoter, uNEG (5′-AAACGCATTGCCATTCTC-3′ and 5′-ATTTCAGTAGCTCAAGCACAG-3′), was used as a negative control. Data was normalized using the percentage input method and plotted relative to that of the IgG control.
Low-density lipoprotein receptor activity assays. Human LDL was isolated and labeled with the fluorescent probe DiI as previously reported 66 . Huh7 cells were transfected in 6-or 12-well plates with miRNA mimics and inhibitors in DMEM containing 10% LPDS for 48 h. Cells were then washed once in 1× PBS and incubated in fresh media containing DiI-LDL (30 µg/ml cholesterol). Nonspecific uptake was determined in extra wells containing a 50-fold excess of unlabeled native LDL (nLDL). Cells were incubated for 8 h at 37 °C to allow for DiI-LDL uptake in screening optimization experiments and for 2 h at 37 °C for subsequent validation experiments. In other instances, cells were incubated for 90 min at 4 °C to assess DiI-LDL binding. At the end of the incubation period, cells were washed, resuspended in 1 ml of PBS and analyzed by flow cytometry (FACScalibur, Becton Dickinson), as previously described 67 . The results are expressed in terms of specific median intensity of fluorescence (M.I.F.) after subtracting autofluorescence of cells incubated in the absence of DiI-LDL.
Fluorescence microscopy. For internalization of an antibody specific to LDLR and DiI-LDL uptake assays, Huh7 cells were grown on coverslips and transfected with a MIR148A mimic or negative-control mimic (CM) in DMEM containing 10% LPDS. 48 h post transfection, cells were cooled to 4 °C for 20 min to stop membrane internalization. Cells were then incubated with an LDLR-specific monoclonal antibody (mAb) (clone C7, Santa Cruz) and 30 µg/ml DiI-LDL for 40 min at 4 °C. Following incubation, cells were gently washed twice with cold medium and shifted to 37 °C to allow for internalization of both LDLR-antibody complexes and DiI-LDL for the indicated times and fixed with 4% PFA. After 5 min of permeabilization with 0.2% Triton X-100 0.2% and 15 min of blocking (PBS, 3% BSA), cells were stained with Alexa Fluor 488-conjugated anti-mouse IgG (Molecular Probes) and TO-PRO-3 iodide (Life Technologies) for 1 h at room temperature. After this, cells were washed twice with 1× PBS and mounted on glass slides with Prolong-Gold (Life Technologies). For LDLR-GFP rescue experiments, Huh7 cells were grown on coverslips and cotransfected with 1 µg LDLR-GFP and 40 nM of CM or miR-148a mimic. 48 h post transfection, cells were incubated with 30 µg/ml DiI-LDL for 2 h at 37 °C (for uptake) or with 30 µg/ml DiI-LDL for 90 min at 4 °C (for binding). Cells were then washed twice with 1× PBS, fixed with 4% PFA and blocked (3% BSA in 1× PBS) for 15 min. Following this, cells were washed twice and mounted on glass slides with Prolong-Gold (Life Technologies). All images were analyzed using confocal microscopy (Leica SP5 II) equipped with a 63× Plan Apo lens. All acquisition parameters of comparable images were maintained constant. Image analysis was performed using ImageJ (NIH) and Adobe Photoshop CS5.
3′ UTR luciferase reporter assays. cDNA fragments corresponding to the entire 3′ UTR of human LDLR and ABCA1 were amplified by RT-PCR from total RNA extracted from HepG2 cells using XhoI and NotI linkers. The PCR product was directionally cloned downstream of the Renilla luciferase open reading frame of the psiCHECK2 vector (Promega). This vector also contains a constitutively expressed firefly luciferase gene, which is used to normalize transfections. Point mutations in the seed region of the predicted miR-148a-binding sites within the 3′ UTR of LDLR and ABCA1 were generated using the Multisite-Quickchange Kit (Stratagene), according to the manufacturer's protocol. All constructs were confirmed by sequencing. COS7 cells were plated into 12-well plates and cotransfected with 1 µg of the indicated 3′ UTR luciferase reporter vectors and miR-148a mimics or control mimics (Life Technologies) using Lipofectamine 2000 (Invitrogen), as previously described 16 . After 24 h of transfection, luciferase activity was measured using the Dual-Glo Luciferase Assay System (Promega). Renilla luciferase activity was normalized to the corresponding firefly luciferase activity and plotted as a percentage of the control (cells cotransfected with the corresponding concentration of control mimic). Experiments were performed in triplicate wells of a 12-well plate and repeated at least three times.
MIR148A promoter assays. A 2.3-kb fragment of the human MIR148A promoter was amplified by PCR from the BAC clone RP11-184C17 with the following primers: 5′-TGATGGCAGACAATAACTCC-3′ and 5′-AAAGT GCTTTCCCATCTTCC-3′. The PCR product was directionally cloned into a PGL3 promoter vector (Promega) using the KpnI and HindIII linkers. For overexpression assays, HeLa cells were cotransfected with 0.5 µg of the indicated p148a-luc constructs, 0.01 µg of Renilla luciferase reporter plasmid and 0.5 µg of nuclear SREBP1c or empty vector control using Lipofectamine 2000. For dose-response experiments, HeLa cells were cotransfected with 0.5 µg of p148a-luc, 0.01 µg of a Renilla luciferase reporter plasmid, and 0.5, 1 or 2 µg of nuclear SREBP1c or empty vector control using Lipofectamine 2000. After 24 h of transfection, luciferase activity was measured using the Dual-Glo Luciferase Assay System (Promega). Renilla luciferase activity was normalized to the corresponding firefly luciferase activity and plotted as a percentage of the control (cells cotransfected with the corresponding concentration of empty vector control) as previously described 68 . Experiments were performed in triplicate wells of a 12-well plate and repeated at least four times. For assays with T090, Huh7 cells were co-transfected with 0.5 µg of p148a-luc and 0.01 µg of Renilla luciferase reporter plasmid using Lipofectamine 2000. 24 h after transfection, cells were washed and treated with vehicle or 3 µM T090 for 12 h. Experiments were performed in triplicate wells of a 12-well plate and repeated at least three times. Luciferase activity was measured as described above and plotted as a percentage of the control (cells treated with vehicle). Experiments were performed in triplicate wells of a 12-well plate and repeated at least three times.
Cholesterol efflux assays. Cholesterol efflux assays were performed as previously described 69 . Briefly, Huh7 cells were seeded at a density of 2 × 10 5 cells per well and transfected with either CM, miR-148a, CI or Inh-148a. After 48 h of transfection, cells were loaded with 0.5 µCi/ml [ 3 H]cholesterol (PerkinElmer) for 24 h. 12 h after loading, cells were incubated with 3 µM T090 to increase the expression of ABCA1. Then cells were washed twice with PBS and incubated in DMEM supplemented with 2 mg/ml fatty acid-free BSA (FAFA-media) (Sigma) in the presence of an ACAT inhibitor (2 µmol/liter) (Sandoz 58-035, SigmaAldrich) for 4 h before the addition of 50 µg/ml human APOA1 in FAFA-media with or without the indicated treatments. Supernatants were collected after 6 h and the level of Mouse studies. Male C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME) and kept under constant temperature and humidity under controlled dark (12 h ) and light (12 h) cycles. For HFD studies, 8-week-old male mice (n = 6 per group) were placed on a chow diet or an HFD containing 0.3% cholesterol and 21% (wt/wt) fat (Dyets, Inc.) for 3 weeks. Liver samples were collected as previously described 16 and stored at −80 °C until total RNA was harvested for miRNA expression analysis.
APOBTg;Ldlr −/+ mice were generated by breeding APOBTg male mice (Taconic) with female Ldlr −/− (Jackson) mice. For miR-148a inhibition experiments, 8-week-old male APOBTg;Ldlr −/+ mice fed a chow diet were randomized into two groups: LNA control (n = 10) and LNA anti-miR-148a (n = 10). Mice received intraperitoneal (i.p.) injections of 5 mg per kg body weight LNA control (5′-ACGTCTATACGCCCA-3′) or LNA anti-miR-148a (5′-TTCTGTAGTGCACTG-3′) oligonucleotides (Exiqon) every 3 d for a total of 2 weeks. 24 h after the final injection, mice were euthanized and hepatic gene expression was analyzed (see above). In another set of experiments, 8-week-old male APOBTg;Ldlr −/+ mice (n = 5 per group) were treated and fed a chow diet as above for 2 weeks, at which point the mice were switched to a HFD (60% fat, Research Diets D12492) and given weekly i.p. injections of LNA control or LNA anti-miR-148a oligonucleotides for 4 weeks. One week after the last injection, the mice were euthanized and hepatic gene expression was analyzed. All animal npg
